|
|
2024's Stock Market Performance
|
|
2024's Stock Market Performance
|
2024's Large Cap Stocks Performance
Here are the best and worst performing Large-Cap Stocks of 2024.
The Large-Cap Company is defined with the market capitalization, trading above 5 billion dollars U.S. as of 10/01/26.
2024's Mid Cap Stocks Performance
Here are the best and worst performing companies of 2024 with the market capitalization, trading between 500 million U.S. dollars and 5 billion dollars U.S. respectively, as of 10/01/26.
2024's Small Cap Stocks Performance
The table shows the best and worst performing companies of 2024 with the market capitalization, trading between 50 million U.S. dollars and 500 million dollars U.S. respectively, as of 10/01/26.
2024's Micro Cap Stocks Performance
The list shows the best and worst performing companies of 2024 with the market capitalization, trading under 50 million U.S. dollars, as of 10/01/26.
Who are the 2024's Stock Market Losers?
SXTP
-89.56%
|
|
|
60 Degrees Pharmaceuticals Inc
Major Pharmaceutical Preparations Industry
SXTP
-89.56%
60 Degrees Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of innovative treatments for infectious diseases, particularly malaria.
|
VRCA
-89.72%
|
|
|
Verrica Pharmaceuticals Inc
Major Pharmaceutical Preparations Industry
VRCA
-89.72%
Verrica Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing medical solutions for dermatological conditions. Their business model revolves around identifying unmet needs in the dermatology market, conducting rigorous clinical research to develop novel therapies, and efficiently bringing these treatments to market through strategic partnerships and collaborations. Verrica Pharmaceuticals aims to enhance patient outcomes by addressing specific dermatological conditions with innovative solutions.
|
CABA
-89.76%
|
|
|
Cabaletta Bio Inc
Biotechnology & Pharmaceuticals Industry
CABA
-89.76%
Cabaletta Bio Inc*s business model revolves around developing and commercializing genetically engineered T cell therapies for the treatment of autoimmune diseases. They aim to utilize their proprietary technology platform to engineer Chimeric AutoAntibody Receptor (CAAR) T cells, which are designed to selectively target and eliminate disease-causing B cells. By focusing on autoimmune diseases with high unmet medical needs, Cabaletta Bio Inc aims to provide effective and personalized therapeutic solutions to patients.
|
LICN
-90.17%
|
|
|
Lichen International Limited
Consulting Services Industry
LICN
-90.17%
Lichen China Limited operates on a business model that focuses on the manufacturing and distribution of electronic products in China. The company engages in partnerships with local suppliers and manufacturers to source components and assemble finished products for both domestic and international markets. Lichen China Limited aims to provide cost-effective solutions with a strong emphasis on quality and innovation to meet the demands of its customers.
|
TVGN
-90.74%
|
|
|
Tevogen Bio Holdings Inc
Biotechnology & Pharmaceuticals Industry
TVGN
-90.74%
The company develops off-the-shelf precision T cell therapies targeting infectious diseases, cancers, and other disorders.
|
MYNZ
-90.77%
|
|
|
Quantum Cyber N v
Major Pharmaceutical Preparations Industry
MYNZ
-90.77%
Mainz Biomed N v operates on a business model focused on the development and commercialization of innovative biomedical solutions. They leverage their expertise in research, development, and manufacturing to create novel biopharmaceutical products with strong market potential. Through strategic partnerships and collaborations, they aim to bring their cutting-edge products to the market, ultimately improving healthcare outcomes.
|
ATPC
-90.78%
|
|
|
Agape Atp Corporation
Medical Equipment & Supplies Industry
ATPC
-90.78%
Agape ATP Corporation provides health and wellness products and programs and invests in renewable energy.
|
BNAI
-90.80%
|
|
|
Brand Engagement Network Inc
Cloud Computing & Data Analytics Industry
BNAI
-90.80%
Brand Engagement Network Inc. develops enterprise-grade conversational AI solutions that connect human intent to systems.
|
EQC
-90.81%
|
|
|
Equity Commonwealth
Real Estate Investment Trusts Industry
EQC
-90.81%
Equity Commonwealth is a real estate investment trust that primarily focuses on the ownership and operation of office properties across the United States. Their business model involves acquiring, managing, and leasing office buildings in strategic locations to generate rental income and maximize long-term shareholder value.
|
SDEV
-90.98%
|
|
|
Stablecoin Development Corporation
Major Pharmaceutical Preparations Industry
SDEV
-90.98%
The company acquires and holds digital assets to participate economically in open digital financial networks.
|
RIME
-91.26%
|
|
|
Algorhythm Holdings Inc
Consumer Electronics Industry
RIME
-91.26%
Algorhythm Holdings operates SemiCab, a company specializing in AI-enabled logistics and distribution software.
|
MKDW
-91.27%
|
|
|
Mkdwell Tech Inc
Electric & Wiring Equipment Industry
MKDW
-91.27%
MKDWELL Tech Inc. is a business company registered in the British Virgin Islands with subsidiaries.
|
AUUD
-92.12%
|
|
|
Auddia Inc
Cloud Computing & Data Analytics Industry
AUUD
-92.12%
Auddia Inc is a technology company that operates on a subscription-based business model. They provide users with access to an audio content streaming platform that includes podcasts, radio shows, and other spoken-word content.
|
HYPD
-92.44%
|
|
|
Hyperion Defi inc
Major Pharmaceutical Preparations Industry
HYPD
-92.44%
Hyperion DeFi manages a treasury of Hyperliquid's token and develops ophthalmic technology.
|
KITT
-92.75%
|
|
|
Nauticus Robotics Inc
Industrial Machinery and Components Industry
KITT
-92.75%
Nauticus Robotics Inc operates on a B2B model, providing autonomous underwater robots for various industries. Their robots are designed to conduct tasks such as inspections, surveys, and data collection in underwater environments with minimal human involvement. The company generates revenue through the sale and maintenance of these robots, as well as by offering specialized software and data analysis services to their clients.
|
ANTX
-93.05%
|
|
|
An2 Therapeutics Inc
Major Pharmaceutical Preparations Industry
ANTX
-93.05%
An2 Therapeutics Inc is a biotechnology company that develops therapeutics for the treatment of rare diseases. Their business model focuses on research and development of innovative drugs that target specific genetic mutations responsible for these rare conditions, aiming to provide effective and personalized treatments. By collaborating with pharmaceutical partners and leveraging their expertise in drug discovery, An2 Therapeutics Inc aims to bring their therapies to market and improve the lives of patients with rare diseases.
|
|
2,811.36 %
PREV.